8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
Subscribe To Our Newsletter & Stay Updated
